The firm is a NASDAQ-listed company that acquires, develops and commercializes promising drugs and technologies by forming and financing subsidiary companies.
All member companies have access to resources necessary for cultivating and maintaining their business such as scientific, clinical, regulatory, manufacturing, legal and financial expertise. Among these key resources are committed investment capital, experienced start-up management with in-house Entrepreneurs in Residence (EIRs), world-class scientific expertise, and shared facilities.
The company does not make equity only investments, but is open to a variety of deal structures to license, co-develop or acquire assets, including traditional milestone-based licensing deals, joint ventures, and option agreements with equity arrangements.
The company focuses primarily on therapeutic opportunities, but will also consider drug delivery devices/technologies. Our current areas of interest include:
– Late clinical stage or marketed dermatology programs/products
– IND ready, clinical or marketed rare disease, oncology, neurology, opthamology, GI or Hepatology
The company has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment